Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Pfizer ( (PFE) ).
On May 19, 2025, Pfizer Netherlands International Finance B.V., a subsidiary of Pfizer Inc., completed a public offering of €3.3 billion in aggregate principal amount of notes with varying maturity dates and interest rates. This strategic financial move, backed by a senior unsecured guarantee from Pfizer Inc., is part of the company’s broader financial strategy to strengthen its market position and ensure operational liquidity.
The most recent analyst rating on (PFE) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Pfizer stock, see the PFE Stock Forecast page.
Spark’s Take on PFE Stock
According to Spark, TipRanks’ AI Analyst, PFE is a Neutral.
Pfizer’s overall stock score reflects a balanced outlook. Strong financial performance improvements and an attractive dividend yield are significant positives. However, technical analysis indicates potential short-term challenges, and missing data for cash flow and the balance sheet in 2024 necessitates cautious optimism. The company’s strategic focus on R&D and cost management, highlighted in the earnings call, supports its long-term growth potential despite current global uncertainties.
To see Spark’s full report on PFE stock, click here.
More about Pfizer
Pfizer Inc. is a leading global pharmaceutical corporation known for its development and production of medicines and vaccines across a wide range of medical disciplines. The company focuses on innovative healthcare solutions and has a significant presence in the global pharmaceutical market.
Average Trading Volume: 54,389,621
Technical Sentiment Signal: Sell
Current Market Cap: $129.8B
Learn more about PFE stock on TipRanks’ Stock Analysis page.